Form 4: Rapport Therapeutics Executive Granted Stock Options

Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, was granted stock options for 84,904 shares of common stock on June 6, 2024.

Summary

• Krishnaswamy Yeleswaram, the Chief Development Officer of Rapport Therapeutics, was granted stock options.
• The transaction occurred on June 6, 2024.
• The stock options are for 84,904 shares of Rapport Therapeutics' common stock.
• The exercise price of the options is $17.
• 25% of the shares will vest on June 6, 2025, and the remaining shares will vest in 36 equal monthly installments thereafter, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral to slightly positive indicator.

Positives

• The granting of stock options to the Chief Development Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Future Outlook

The vesting schedule suggests an expectation of continued service from the Chief Development Officer for at least the next three years.

Industry Context

Granting stock options is a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Development Officer to drive company growth.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates